Acute Myeloid Leukemia With Minimal Differentiation:<i>A Multiple Parameter Study</i>

Cohen, Patti; Hoyer, James D.; Kurtin, Paul J.; Dewald, Gordon W.; Hanson, Curtis A.

doi:10.1093/ajcp/109.1.32

Cited by 42 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,3,[5][6][7]11,28,31 In this study, no consistent chromosomal abnormality was detected within the AML-M0 cohort, though cytogenetic data were limited. The classic favorable AML translocations (those involving CBF, including t(8;21), and inv 16 ), present in more than 20% of non-M0 AML patients, were not present in any AML-M0 patient.…”

Section: Discussionmentioning

confidence: 94%

Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961

Barbaric

Alonzo

Gerbing

et al. 2006

Blood

View full text Add to dashboard Cite

To assess the impact of minimally differentiated acute myeloid leukemia (AML-M0) morphology in children, we analyzed 2 sequential Children's Cancer Group AML clinical trials. We compared presenting characteristics and outcomes of 82 CCG-2891 and CCG-2961 patients with de novo, non-Down syndrome (DS) AML-M0 with those of 1620 patients with non-M0 AML, and of 10 CCG-2891 patients with DSassociated AML-M0 with those of 179 with DS-associated non-M0 AML. Morphology and cytogenetics were centrally reviewed. The non-DS AML-M0 children had a lower white blood cell (WBC) count (P ‫؍‬ .001) than their non-M0 counterparts and a higher incidence of chromosome 5 deletions (P ‫؍‬ .002), nonconstitutional trisomy 21 (P ‫؍‬ .027), and hypodiploidy (P ‫؍‬ .002). Outcome analyses considering all children with non-DS AML demonstrated no significant differences between M0 and non-M0 patients. Analyses restricted to intensive-timing CCG-2891 and CCG-2961 demonstrated comparable complete response (CR) rates (79% and 78%) between non-DS M0 and non-M0 patients. Overall survival (OS) from diagnosis (38% ؎ 14% versus 51% ؎ 3%; P ‫؍‬ .160) was not significantly different between the 2 groups. OS from end of induction (45% ؎ 17% versus 63% ؎ 3%; P ‫؍‬ .038), event-free survival (EFS; 23% ؎ 11% versus 41% ؎ 3%; P ‫؍‬ .018), and disease-free survival (DFS; 31% ؎ 14% versus 52% ؎ 3%; P ‫؍‬ .009) were inferior in the M0 group. There was no significant outcome difference between DS-associated AML-M0 and non-M0 children. This study suggests that intensively treated non-DSassociated AML-M0 children have an inferior outcome compared with children with non-M0 AML. (Blood.

show abstract

Section: Discussionmentioning

confidence: 94%

Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961

Barbaric

Alonzo

Gerbing

et al. 2006

Blood

View full text Add to dashboard Cite

show abstract

“…In one study, reported that the median age for 128 patients with AML was 67 years (range, 18 to 94) (Lerch et al, 2009). Other study, showed the median age of 17 patients with AML-M0 was 62 years that patients were male (Cohen et al, 1998). Data on 184 patients [MDS and AML], showed a the median age of 71.6 years (range, 29-92 years) (Merkel et al, 2013).…”

Section: Discussionmentioning

confidence: 96%

Prognostic Factors and Survival in Acute Myeloid Leukemia Cases: a Report from the Northeast of Iran

Allahyari

Tajeri²,

Sadeghi³

2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

In all patients, 76% had fever and 50% consumed amphotericin. T(15;17)(q22;q21) had the most prevalence (37.7%) compared to other forms. Out of 92 patients, O+(30.4%) was the most common blood group and AML-M5 (28.3%) the most common subtype. There was a significant difference in survival based on WBC and consumption of amphotericin B (P<0.05). Conclusions: WBC level, fever and consumption of amphotericin B proved to be factors for survival of AML patients. The mean age for patients in Iran is lower than other areas in the World and also survival in this study was higher than in other studies.

show abstract

“…CD13 and CD33 are the most sensitive myeloid markers. The assigning of myeloid lineage relies on identifying the expression of antigens characteristic of early myelomonocytic differentiation, including CD13, CD15, CD33, CD64, CD117, and cytoplasmic myeloperoxidase (Bain BJ et al, 2002;Chang CC et al, 2000;Cohen PL et al 1998;Craig FE & Foon KA, 2008;Wood BL, 2007). CD64 is expressed in AML subtypes M0 to M5 in varying intensities: strong expression characterizes AML M5, whereas heterogeneous, dim, or moderate expression is seen in M0 through M4 subtypes.…”

Section: Hla-dr In Amlmentioning

confidence: 99%

Diagnostic Approach in Acute Myeloid Leukemias in Line with WHO 2008 Classification

Goyal¹,

Gayathri²

2012

Myeloid Leukemia - Clinical Diagnosis and Treatment

View full text Add to dashboard Cite

Acute Myeloid Leukemia With Minimal Differentiation:A Multiple Parameter Study

Cited by 42 publications

References 15 publications

Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961

Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961

Prognostic Factors and Survival in Acute Myeloid Leukemia Cases: a Report from the Northeast of Iran

Diagnostic Approach in Acute Myeloid Leukemias in Line with WHO 2008 Classification

Contact Info

Product

Resources

About